Alcon Rides New Product Wave to 8 Per Cent Sales Growth, but One-Off IOL Writedown Wipes Out Quarterly Profit

Global eye care giant Alcon has posted second-quarter net sales of US$2.8 billion (approx. A$3.95 billion), an 8 per cent lift on the prior corresponding period, as newer additions to its surgical and vision care portfolios continue to gain ground with clinicians and patients.

But the headline growth number tells only part of the story. A pre-tax, non-cash charge of US$402 million (approx. A$571 million) tied to the discontinuation of the company's PowerVision intraocular lens programs dragged reported operating income down to just US$11 million (approx. A$16 million) for the quarter, from US$247 million (approx. A$351 million) a year earlier, effectively wiping out reported profit even as the underlying business strengthened.

Growth led by newer platforms

Alcon chief executive David Endicott pointed to the company's recent launch cadence as the driver behind the result, name-checking the Unity surgical platform, the PanOptix Pro presbyopia-correcting IOL and the dry eye treatment Tryptyr as products "reinforcing the strength" of the company's innovation pipeline.

Both of Alcon's reportable segments grew at a similar clip. Surgical net sales rose 8 per cent to US$1.6 billion, with the Equipment/Other category, buoyed by early Unity uptake, up a striking 26 per cent. Consumables grew 6 per cent on continued procedural volume and pricing gains, even as the company flagged ongoing softness in the broader cataract market. Implantables sales rose a more modest 2 per cent, with PanOptix Pro's strong performance offset by competitive pressure and weaker surgical glaucoma sales.

Vision Care also delivered an 8 per cent gain to US$1.2 billion. Ocular health, home to Tryptyr and Systane, jumped 13 per cent, while contact lenses grew 5 per cent on newer product innovation, even as legacy lens ranges continued to decline.

PowerVision wind-down behind the profit hit

The quarter's reported bottom line was overshadowed by Alcon's decision to discontinue the IOL programs it acquired from PowerVision back in 2019, after a review of the latest clinical data found the lenses were producing unpredictable post-surgical visual outcomes in a subset of patients that could not be resolved despite repeated development attempts.

The company was at pains to stress the charge is non-cash and doesn't touch its balance sheet or its longer-term financial targets. Strip that item out, along with routine intangible amortisation and other core adjustments, and the picture looks considerably healthier: core operating income rose 17 per cent to US$574 million, with core operating margin up 1.5 percentage points to 20.6 per cent. Core diluted earnings per share came in at US$0.84, up 11 per cent on the prior year.

Guidance nudged higher

Alcon left its full-year net sales growth outlook unchanged at 5 to 7 per cent in constant currency, but lifted both its core operating margin and core diluted EPS growth guidance. The former now expected to expand 90 to 190 basis points versus a prior 70 to 170, and the latter now guided at 12 to 15 per cent growth, up from 10 to 13 per cent.

The company is also banking on a roughly US$60 million US tariff refund landing in the third quarter, part of an expected full-year net tariff impact of US$40 million to US$90 million.

Capital returns and other developments

Alcon returned US$469 million to shareholders in the quarter via dividends and buybacks, taking its year-to-date total to US$538 million, with roughly US$1.2 billion still available under its existing repurchase authorisation.

Elsewhere, the company used the results release to highlight a newly announced non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting IOLs, pairing Alcon's optical designs with RxSight's light-adjustable lens technology, a partnership likely to draw close attention from cataract surgeons watching the premium IOL space evolve.